TRIALS AND TRIBULATIONS
T e ability of small interfering RNA (siRNA) to silence target genes with high eff ciency and specif city has stimulated ef orts to develop these molecules as therapeutic agents.
is approach has attracted particular interest within oncology, for which many important therapeutic targets have thus far proven to be undruggable. Several early-phase trials have reported clinical responses in cancer patients af er RNA interference (RNAi) therapies designed to thwart translation of mRNAs that encode vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP) (1), the K-Ras G12D mutant (2) , and the M2 subunit of ribonucleotide reductase (RRM2) (3) ( Table  1) . ese trials not only highlight the feasibility of delivering siRNAs into tumors but also demonstrate their ability to selectively decrease gene expression as well as their potential use in cancer management.
Despite the success of these clinical trials, improvements in RNAi-based therapeutics are needed in a variety of areas. Delivery ef ciency of siRNAs into tumors, choice of RNAi targets, and safety are the three main areas that currently limit the ability of RNAi technology to reach its maximal potential in the clinic. For instance, only a fraction of tumor samples from cancer patients with liver involvement that were examined in the recent ALN-VSP trial (NCT01158079) showed decreased levels of target-gene expression (1) ; furthermore, the size of the decrease did not correlate with therapeutic response. In fact, in all of the early-phase siRNA cancer trials, there was minimal evidence of mRNA cleavage products in the tumors [as determined by the rapid amplif cation of 5′ complementary DNA ends (5′RACE) assay], which is a critical indicator of RNAi activity (1, 3) . On-and oftarget toxic ef ects (such as infusion-related reactions, proinf ammatory cytokine induction, or spleen toxicity) were also observed (1, 3) .
e lack of biomarkers associated with biological response further prevents optimal clinical trial design.
ese critical issues highlight key considerations for future development of RNAi-based cancer therapeutics (Fig. 1) . In this article, we discuss the strengths and weaknesses encountered in these early trials and provide recommendations for strategies to enhance the likelihood of making RNAi-based therapy a viable part of oncology care.
CAN NANOCARRIERS DELIVER?
An ef ective delivery system is crucial for the clinical use of RNAi nucleotides given their susceptibility to nuclease degradation and inability to cross cell membranes. Tumoral localization. e size, shape, surface charge, and composition of nanocarriers are critical factors in tumor localization.
e enhanced permeability and retention (EPR) ef ect in tumors is well-established and forms a primary principle for delivering therapeutics to tumors. To take advantage of the EPR ef ect, the particles should ideally be 50 to 200 nm in diameter and possess long-circulating properties.
is principle has guided the design of many nanoparticles currently being evaluated in human trials (1, 3, 5) , but the dif erences of each system results in distinct biodistribution patterns of particles or siRNAs.
For instance, the PEGylated Atuplex system, currently being evaluated in patients with advanced solid tumors in the Atu027 trial (NCT00938574), accumulates mainly in the lung and tumor vasculature, likely owing to the incorporation of cationic lipids (5). In contrast, PEGylated cyclodextrin nanoparticles (3) or LNPs that contain ionizable lipids (such as DLin-DMA or DLin-MC3-DMA) promote localization in the tumor cells themselves (1) . e extent of tumor accumulation, therefore, depends on the specif c properties of each component in the delivery carrier. is was clearly demonstrated in the recent TKM-PLK1 study (NCT01262235) in which a severalfold increase in drug exposure (measured by the area under the curve) was reported with optimized DLinDMA-based LNPs (6) compared with the earlier generation of DLinDMA-based LNPs used in the ALN-VSP02 trial.
Detailed preclinical nanoparticle characterization and investigation of the ef ects of nanoparticles on siRNA distribution patterns in vivo are critical for increasing the chances of clinical success. Although general characteristics are commonly described for RNAi delivery systems, we lack detailed characterization of the distribution of individual particles with dif erences in the sizes, charges, and shapes (7) . A critical question is whether particle uniformity is important for ef ectiveness because distinct subsets of particles in a formulation may have preferential tumor-localization capability. Investigation into this concept is important to ensure a thorough understanding of the physicochemical properties required for optimal tumoral delivery. Assessments of the timeframe of delivery to tumor sites and the extent, rate, and duration of silencing are among the most crucial next steps for clinical development of siRNA nanocarriers.
Intratumoral mobility. Once in tumors, nanocarriers must be taken up ef ectively by the target cell population. Intratumoral distribution of nanoparticles is controlled by their physicochemical properties, especially size (8) , charge (9) , and the extent of their interaction with the extracellular matrix and soluble factors present in the tumor microenvironment. Patchy tumoral delivery patterns were documented in many preclinical studies and in the CALAA-01 trial (NCT00689065) (10), suggesting that the RNAi variability observed in recent cancer-siRNA clinical trials (1, 3) may not have been an indication of poor eff cacy, but rather inconsistent siRNA delivery to the tumor areas from where the biopsies were taken.
Previous attempts to improve intratumoral mobility of nanoparticles have included the use of neutral charged carriers (9) and the incorporation of agents such as hyaluronidase or tumor-penetrating peptides (10) . e peptide approach, however, requires safety evaluation. A recent study highlighted an alternative strategy in which a short-acting inhibitor (LY364947) of transforming growth factor-β type I receptor (TGFβR1) that transiently decreases pericyte coverage of the endothelium was coadministered with polymeric micelles (70 nm) (8); inhibition of TGFβR1 enhanced the extravasation and penetration of particles from the bloodstream into poorly permeable pancreatic tumors.
us, coadministration of a TGFβR1 inhibitor with neutral particles <70 nm in diameter can enhance the tumoral delivery of RNAi therapeutics.
Tumor cell uptake. Nanocarriers can be taken up by tumor cells through interaction with cell membranes (for example, via macropinocytosis) or cell-surface protein transporters (7) . Although the e% ciency of this process is highly dependent on particle size, charge, and surface characteristics, the presence of targeting ligands on the nanoparticle surface can enhance their uptake by tumor cells. e use of ligands is especially critical when a stable steric barrier has been created on the nanoparticle surface [for example, long-chain lipid-anchored polyethylene glycol (PEG)], because this inhibits the interaction of nanoparticles with tumor cell membranes.
Ligands specif c for proteins overexpressed on the surface of cancer cells, such as prostate-specif c membrane antigen or transferrin receptors, have been widely tested in preclinical and clinical studies. However, many of these technologies have yet to be translated beyond clinical trials because of the heterogeneity in tumoral expression and lack of tumor specif city of the targeted protein. Tumor cells that lack receptor expression could selectively grow under such settings, making strategies that incorporate multiple tumor-specif c surface ligands a more desirable approach.
Recently described high-throughput screening of large aptamer or peptide libraries in vivo hold promise for the rapid identif cation of highly specif c tumor-targeting ligands (11, 12) . In these studies, pools of aptamers or peptides are administered intravenously into tumor-bearing mice. e aptamers or peptides that are bound in tumors are then extracted and reinjected into animals for several rounds of selection. Such strategies have identif ed targeting ligands such as aptamers that bind p68 for treatment of colon cancer metastases (11) and peptides that can bind to the prostate tumor vasculature with high a% nity (12) .
ese high-throughput screens pinpoint tumor-selective ligands that can be used to coat nanoparticles for e% cient delivery of siRNAs into tumors. However, careful characterization of the ligand-to-nanoparticle ratio for each ligand is required for clinical translation. A mixture of nanocarriers with each particle coated with a single ligand may provide a more feasible approach for clinical development. e assessment of delivery eff cacy of these tumor-targeted nanocarriers in vivo requires tumor models that mimic the heterogeneity in ligand binding partners observed in human tumors.
Intracellular traf cking.
Once the nanocarrier is inside the cell, its ability to mediate e% cient release of the siRNA payload is highly dependent on the biomaterials used in the nanocarrier. is was evident in recent RNAi trials in which a dose of 1 mg/kg siRNA was required to achieve 38% knockdown of transthyretin in liver when delivered by using f rst-generation LNPs (DLin-DMA), whereas a dose of only 0.3 mg/kg achieved 85% knockdown by using secondgeneration LNPs (DLin-MC3-DMA) (4). Although the structure-activity relationship for both lipid-and polymer-based carriers had been well-characterized, an elegant study by Gilleron and colleagues identif ed a major bottleneck in ef ective siRNA delivery via LNPs (13) . e authors reported that in cancer cells or hepatocytes, only 1 to 2% of endosomal siRNAs were able to escape into the cytoplasm when delivered by using second-generation LNPs. Such detailed endosomal studies have not been consistently performed for other types of carriers.
Strategies to improve endosomal escape of siRNAs into the cytoplasm include the use of endosomal release agents such as TAT-fusion peptide or fusogenic lipids (7) . However, such agents typically suf er from safety concerns owing to toxicity or immunogenicity. Recently, a polymer-based dynamic polyconjugate (DPC) delivery system was reported to overcome this issue (14) . e amphipathic, endosomolytic N-acetylgalactosamine-conjugated melittin (bee venom)-like peptide incorporated in this system activates only in the acidic environment of the endosome and can prevent premature activation and resultant toxic ef ects. e combinatorial use of this DPC system with cholesterol-conjugated siRNAs was shown to reduce the siRNA dose required for apolipoprotein B (apoB) knockdown in mice when compared with cholesterol-conjugated siRNAs alone [0.05 mg/kg (15) versus 50 mg/kg, respectively] (16). In hepatitis B virus (HBV)-infected patients, single injection of DPC-delivered siHBV also revealed minimal toxicity, further demonstrating DPC's utility in RNAibased therapy (17) .
Despite the noted advances, we still need high-throughput techniques for identifying new biomaterials that can promote eff cient intracellular tra% cking of siRNAs.
e combined use of such a carrier with potent, chemically modif ed siRNAs [for example, MePS2-modif ed (18) ] that have a high a% nity for the RNA-induced silencing complex (RISC) (Fig. 1) can substantially improve the bioavailability of RNAi therapeutics. Love and colleagues recently developed an in vitro cell-based technology that allowed them to screen a large library of more than 120 structurally diverse lipidoids for their delivery potential. e delivery e% ciency was measured by the extent of siRNA-mediated luciferase down-regulation in luciferase-expressing HeLa cells (19) . Although successful identif cation of potent lipidoids such as C12-200 was achieved with this approach, strategies to combine such high-throughput screens with methods that assess endosomal release for each biomaterial are critical for future rational design of siRNA nanocarriers.
RNAi TARGET SELECTION
e success of an RNAi-based therapy in clinical trials rests on careful selection of the siRNA targets. Recent advances in wholegenome RNAi screens provide a highthroughput means by which new targets for cancer treatment can be identif ed. An ideal target should (i) have a biomarker that can predict the biological and clinical response of RNAi; (ii) cause tumor regression upon silencing; and (iii) be preferentially expressed in tumors. Many of the RNAi targets currently being evaluated in clinical trials fall short of these criteria, resulting in complications such as on-target toxicity [for example, spleen toxicity (1)] or lack of an effective strategy for patient selection (3, 5) . Here, we highlight critical issues and discuss recently developed strategies that may facilitate the future design of RNAi therapeutics.
Screens for attractive targets.
A variety of conserved mutations have been shown to govern tumor biology and response to therapies. us, RNAi screens should ideally be performed in tumor models with def ned molecular characteristics. Clinically relevant mutational signatures identif ed in various cancers provide an excellent framework for siRNA target selection (20) . e combined use of selective mutation manipulation and whole-genome RNAi screening could facilitate the rapid identif cation of cancer survival genes and candidate markers of therapeutic response. Already, in vitro RNAi screening by use of cell lines with distinct mutations has identif ed therapeutically important targets such as GATA2 (21) and BRCA1 (22) in tumors with KRAS or CCNE-1 mutations, respectively.
However, this approach has limitations. First, even in carefully controlled conditions in vitro screening cannot mimic human physiology. Second, it is of en di% cult to identify cancer-specif c survival genes because many such genes also have functions for normal physiology.
erefore, drugs targeting these genes can lead to on-target toxic ef ects and consequently hinder clinical development. In an attempt to overcome these limitations, researchers have performed genome-wide RNAi screens in animal models (23, 24) . For instance, Beronja and colleagues transduced a pool of small hairpin RNA (shRNA)-expressing lentivirus into the embryonic epidermis in Credriven Hras G12V mice. By toggling Hras
G12V
of and on, the researchers were able to differentiate between genes that are universally critical for the survival of all cells (not preferable for pharmacological interventions) and those that are functionally important for cancer cell growth (potential candidates for therapeutic targeting). e major advantage of this approach is its ability to rapidly identify genes of potential therapeutic interest while having a biomarker (the mutational signature) that is predictive of therapeutic response. e use of this technology to study genetic vulnerabilities in the presence of other clinically relevant mutations will be the next major challenge.
Synergistic strategies. Prioritization of targets identif ed through RNAi screens is of central importance for successful clinical translation. Currently, we lack an integrative approach for target selection that combines information from patient omics data, high-throughput screens of various kinds, and tumor-specif c gene expression patterns. Integrated analyses can be facilitated by the availability of large-scale data, such as that from e Cancer Genome Atlas (TCGA), and would provide a robust framework for prioritizing targets that have high translational potential. Strategic use of the TCGA database has already yielded some promising results (25) with targets such as the protein-tyrosine kinase Eph receptor A2 (EphA2); agents that target this tumor-promoting cell-surface receptor are now entering clinical development for the treatment of solid tumors. In addition to targeting a single gene, RNAi technology is ideally suited for achieving coextinction or therapeutic synergy in cancer treatment. Such a strategy could be important for overcoming compensatory effects (such as drug resistance) typically observed in cancer cells af er knockdown of a single target. is can be achieved through the use of multiple RNAi sequences, and numerous preclinical studies have reported synergistic antitumor ef ects by using this approach (22, 26) . Also emerging is the con-cept of combining microRNAs (miRNAs)-naturally occurring small noncoding RNA molecules-with siRNAs to achieve a synergistic ef ect and thwart siRNA resistance. For example, in a recent study a synergistic antitumor ef ect was reported when miR520d-3p was codelivered with an siRNA targeted against EphA2, a downstream target of miR-520d-3p (25) . erapeutic synergy resulted in part from the ability of miR520d-3p to inhibit a second target, EphB2, another Eph receptor that promotes cancer growth. Coupling careful selection of combinatorial RNAi targets with robust validation in clinically relevant animal models could forge a new path in cancer therapeutics that has been previously inaccessible with single-treatment strategies.
SAFETY OF RNAi THERAPEUTICS
Toxic ef ects can arise af er nonspecif c uptake of nanocarriers by immune and endothelial cells or by nonspecif c accumulation in f rst-pass organs such as the spleen and liver (1, 3, 4) . ese issues can be overcome by dose reduction, the use of biocompatible carriers that exhibit favorable biodistribution patterns, or chemically modif ed siRNAs. Development of nanoparticles with high tumor-localization capability (6) as well as potent carriers that require lower dosage of siRNAs (4) can improve the safety prof les of RNAi therapeutics. e use of nonimmunogenic siRNA constructs together with immune suppression agents has also largely eliminated the intolerable immune reactions observed in patients in the TKM-apoB trial [NCT00927459; (27) ].
Despite these improvements, infusionrelated reactions or complement activation are still the most commonly observed adverse ef ects in siRNA clinical trials (4). Moreover, long-term safety of siRNA delivery systems has not been established. In an ef ort to improve the safety prof le of siRNA carriers, Maier and colleagues developed a series of lipids that incorporate ester linkages into their hydrocarbon chain region (28) . Af er intravenous administration in mice and nonhuman primates, this design promotes rapid metabolism of the lipids into more hydrophilic, water-soluble products, leading to a >1000-fold increase in elimination from the primary site of RNAi activity compared with that of parental lipids. is is advantageous because prolonged accumulation of LNPs in the body, long after the siRNA has been delivered to target organs, can lead to adverse ef ects. Indeed, improved tolerability was observed for the lead candidate, L319 (a DLin-MC3-MDA lipid with an ester modif cation), showing reduced liver transaminase levels at doses >3 mg/kg when compared with that of the parental lipid. No dif erence was detected in the ability of L319+factor VII siRNAs and DLin-MC3-MDA+factor VII siRNAs to silence factor VII in mice, demonstrating the feasibility of L319 for future design of LNPs. Although its utility for cancer treatment along with its safety prof les in patients remain to be determined, this study provides a blueprint for improving the biocompatibility of other types of siRNA carriers.
PUTTING IT ALL TOGETHER
Multifunctional nanocarriers represent a major advance for cancer RNAi therapeutics, with early successes already observed in clinical trials (1, 3, 5) . Ef orts continue toward improving potency, pharmacokinetic prof les, and biocompatibility of existing delivery carriers. Some emerging vectors may also of er singular opportunities to overcome multiple delivery barriers and at the same time possess favorable characteristics for clinical translation. Examples include exosomes (29) and self-assembled nucleic acid nanoparticles (30) .
Each of these vectors has particular strengths and potential weaknesses. For instance, exosomal carriers possess favorable pharmacokinetic prof les yet suf er from drawbacks such as low siRNA loading eff ciency. Self-assembled DNA tetrahedral nanoparticles of er the advantage of particle size or charge uniformity that cannot be achieved by existing delivery carriers but rely heavily on the use of targeting ligands for cell entry. Although we are optimizing the delivery e% cacy of each system, ef orts should also focus on avoiding of -target toxic ef ects without adding a degree of complexity that limits large-scale production.
Lessons learned from recent trials should be used to guide the design of preclinical and clinical studies for these innovative platforms. Key points to consider are summarized below.
Goal 1: Particle characterization.
(i) Optimal physicochemical characteristics of a given delivery platform must be identif ed for ef ective tumor delivery. Although neutral particles with sizes ranging from 50 to 100 nm are typically desired, the requirement may dif er between various delivery platforms and tumor models.
(ii) Although the bulk characteristics are routinely reported, careful control of the distribution of physicochemical properties (size, shape, and charge) within a given formulation that may govern their fate in biological f uids and tissues is currently lacking.
(iii) Particle characterization must be performed to assess the exact siRNA:carrier or carrier:ligand ratio and stoichiometry for each individual particle within a given formulation.
Goal 2: Thorough validation of the delivery system. (i) E% cacy assessments of delivery platforms must be performed in vivo with a model that closely resembles characteristics of human tumors. In vitro assessments appear to provide minimal value.
(ii) Assessment of biodistribution and pharmacokinetic prof les of new delivery carriers is routinely performed by using f uorescently labeled siRNAs or nanocarriers. Although this method is convenient, it does not provide information regarding the functionality or intactness of siRNA molecules. Recent clinical trials that used the highly sensitive and sequence-specif c enzymelinked immunosorbent assay (3) or stemloop polymerase chain reaction techniques (1) serve as blueprints for future preclinical pharmacokinetic evaluation of siRNA nanocarriers.
(iii) Careful examination of the impact of dif erent formulation parameters on the distribution pattern of nanocarriers within tumors is needed.
(iv) Stringent criteria should be used preclinically to thoroughly assess the ef ectiveness of a given carrier to deliver siRNAs to a target cell population. Although the level of mRNA or protein knockdown in tumors is routinely assessed, testing for the presence of siRNA-mediated mRNA cleavage products via the 5′RACE assay (a direct indicator of RNAi activity) should be, but rarely is, performed.
(v) Once delivery e% cacy has been established in vivo, examination of a nanoparticle's cellular uptake and intracellular traff cking pattern should be performed to facilitate future design and optimization of delivery carriers. (ii) Strategies to identify new RNAi target genes should include analysis of clinical relevance, biological relevance, and gene expression patterns using information from well-annotated patient databases such as TCGA.
(iii) Animal models should be carefully selected to best emulate human disease. Reliable biomarkers for assessment of biological response end points are needed.
Goal 4: Safety prof le of the delivery system. (i) Relevant toxicology, pharmacology, and pharmacokinetics in preclinical studies should be discussed early in development with the regulatory agencies such as the U.S. Food and Drug Administration (FDA). e Nanotechnology Characterization Laboratory established by the U.S. National Cancer Institute serves as a resource for researchers to evaluate the feasibility of their delivery platforms for cancer therapies.
(ii) Assessment of toxic immunemediated reactions is not routinely performed in the preclinical phase of nanoparticle development. Such ef ects could lead to hypersensitivity reactions and should be assessed af er administration of multiple doses in animals.
Goal 5: Pharmaceutical feasibility.
(i) e ability to scale up the production of nanocarriers while maintaining careful control of the physicochemical properties of the particles as well as the siRNA:carrier ratio is critical for the clinical development of a nanocarrier.
(ii) Cost-e% ciency should be considered while designing new nanocarriers.
(iii) Appropriate protection of intellectual property for delivery technologies is critical for a path toward clinical translation.
TRANSLATING INTO SUCCESS
Development of RNAi therapeutics provides new opportunities for cancer treatment, but the complexity of the task requires collaboration among materials scientists, imaging experts, cancer biologists, bioinformaticians, and clinicians. Early consultation with FDA is necessary for successful initiation of earlyphase clinical trials for RNAi therapeutics. Only through fostering this working model can we overcome current challenges and move the f eld forward rapidly.
New clinical trial designs should also be considered for RNAi therapeutics. Current phase 1 trials suf er from insu% cient pharmacodynamics validation (1, 3) . Moreover, core needle biopsies do not always give suff cient material for valid end-point assessment. Phase 0 cancer clinical trials may be ideally suited for rapid assessment of the clinical feasibility of a given RNAi therapeutic strategy. When coupled with planned surgery af er treatment, su% cient tumor samples can be obtained to carefully assess tumor localization of the nanocarriers as well as the ef ectiveness of target modulation. Such trial designs could streamline the process of nanocarrier development because less-extensive preclinical toxicology data are required for phase 0 trials than for phase 1 trials, and inef ective nanocarriers can be eliminated rapidly. RNAi technology represents a rapidly emerging platform for personalized cancer therapy. Although the technology has shown promise in early-phase clinical trials, seminal work is required for siRNAs to revolutionize the clinical care of cancer patients.
